



Subject: Update on Anemia ID Genetic Testing Program

For more than five years, Agios has been committed to breaking down barriers in genetic testing for patients with hemolytic anemias. Our collaboration with Revvity Omics resulted in the creation of the Anemia ID program, which offers free testing for patients with suspected hereditary anemias. This initiative aimed to provide crucial information that could guide informed decisions, improve quality of life, and identify new treatment options. Agios took a bold step by creating this sponsored testing program, which was unprecedented in this field.

Anemia ID was intended to serve the broader hemolytic anemia community, including pyruvate kinase (PK) deficiency, a disease that was previously not well known or understood. We believe that Anemia ID has indeed helped to make meaningful progress for the PKD community by improving awareness and diagnosis of this condition.

We continue to be deeply committed to the PKD community and to driving progress in disease understanding, diagnosis, treatment and patient support. We are also advancing programs in additional rare blood disorders, including thalassemia and sickle cell disease. As we continue to evolve to support a growing group of patients and providers across PK deficiency, thalassemia, sickle cell disease, and more, we must carefully prioritize our efforts to support this broader mission and have a positive impact across all of these communities. Therefore, we have made the difficult decision to discontinue the Anemia ID program.

Going forward we will continue to provide robust financial and other support for pyruvate kinase deficiency patients through our myAgiOS support program.

**Anemia ID test kits and referrals to Informed DNA will be available through December 15, 2024. All specimens received prior to December 31, 2024, will be tested at no cost under the Anemia ID program.**

After this date, the existing Anemia ID next-generation sequencing (NGS) panel, which examines 50+ genes and 30+ disorders, will be commercially available independently through Revvity Omics. Additionally, there are other commercial and academic labs offering NGS panel tests for hereditary anemias.

We take pride in the groundbreaking work accomplished during the past half-decade. Our partners have meticulously analyzed thousands of samples, leading to hundreds of confirmed diagnoses that have positively impacted countless lives, and many have also received genetic counseling through InformedDNA. This achievement reflects our dedication to advancing patient care.

We are immensely proud of the positive impact Anemia ID has had for patients. Our commitment to innovation and improving healthcare remains unwavering. We appreciate your ongoing support and look forward to continuing our journey together.

PKD-US-1276